The purpose of the study: to evaluate the protective properties of a multi-strain probiotic in the development of gastrointestinal disorders with impaired microbiota during antibiotic therapy (ABT) for 1 to 3 years old children with acute respiratory infection (ARI). Objectives of research: to evaluate the incidence of development and severity of gastrointestinal disorders, as well as changes in the dynamics of intestinal microbiota using 16S rRNA gene sequencing in 1 to 3 years old children with ARI and receiving ABT, depending on the addition of a multi-strain probiotic to the treatment regimen. Materials and methods: the study involved 148 children from 1 to 7 years old both girls and boys (54 children were 1 to 3 y.o. and 65 were 3 to 7 y.o.), hospitalized within first 3 days of URTI symptoms (acute upper respiratory tract infection – URTI) and 29 healthy children from outpatient department as a healthy control. Present article covers data and outcomes of younger age group – 54 children 1 to 3 years old, hospitalized within first 3 days of illness and 10 healthy children of the same age range. The main group included 27 children who received ABT + multi-strain probiotic Bac-Set® Baby for the entire period of ABT and extra 14 days after its discontinuation; the comparison group included 27 children who received only ABT. The frequency of bowel movements was assessed, feces were evaluated accordingly to Bristol scale upon admission to the hospital, befor e discharge from the hospital (in 7 ± 2 days), and in 21 ± 2 days from the beginning of ABT. Results. The frequency of bowel movements after 7 ± 2 days and 21 ± 2 days from the start of therapy was significantly higher in the comparison group than in the main group (81.5% and 26% versus 7.4% and 7.4%, respectively). The stool rate accordingly to Bristol scale in the comparison group changed up to moderate diarrhea, which was not registered in the main group. In both groups, an increase in alpha-diversity of microbiota was observed within 2-week period after discontinuation of antibiotic therapy. During the study, adverse reactions of multi-strain probiotic were not found. Conclusions. The results allow to suggest that the use of Bac-Set® Baby multistrain probiotic helps to maintain the stability of the microbiome during antibiotic therapy and in the recovery period after it. The use of Bac-Set® Baby with antibacterial therapy has a protective effect on gastrointestinal upsets incidence rate and reduces the negative impact on microbiome.
Согласно данным литературы, новая коронавирусная инфекция COVID-19 у детей развивается реже (до 10% в структуре инфицированных вирусом SARS-CoV-2) и протекает легче, чем у взрослых, а летальные исходы – единичны. Однако у детей, перенесших легкие формы COVID-19, может развиваться мультисистемный воспалительный синдром (МВС). Для МВС характерно поражение респираторного и желудочно-кишечного тракта (боль в животе, рвота, диарея), менингеальные признаки и признаки поражения сердечно-сосудистой системы (неспецифические изменения на ЭКГ по типу миокардита, систолическая дисфункция в сочетании с низким систолическим артериальным давлением, но без развития тромбоза коронарных артерий), а также лейкопения с выраженной лимфопенией, тромбоцитопенией, повышением уровня ферритина и маркеров миокардита. Возможно появление кожной сыпи, хейлита, цервикальной аденопатии и менингизма. Развитие тяжелого МВС у детей может происходить через 2-6 недель после перенесенных легких форм COVID-19. Это диктует необходимость раннего назначения противовирусных средств для экстренной профилактики в очаге инфекции и лечения легких форм болезни у детей согласно действующим клиническим рекомендациям.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.